leadf
logo-loader
viewMountain Valley MD Holdings Inc

Mountain Valley MD files a patent for dosed adjuvant with potential application for polio vaccine

Mountain Valley MD (CSE: MVMD) Director of Life Sciences Mike Farber joined Steve Darling from Proactive with news the company has applied for a patent to cover a novel dose sparing adjuvant with a potential application for Polio IPV delivery and the broader category of vaccines.

Farber gives detail about what that patent covers and also what the next steps will be for testing and verification.

Quick facts: Mountain Valley MD Holdings Inc

Price: 1.34 CAD

CSE:MVMD
Market: CSE
Market Cap: $334.42 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Mountain Valley MD Holdings Inc named herein, including the promotion by the Company of Mountain Valley MD Holdings Inc in any Content on the...

FOR OUR FULL DISCLAIMER CLICK HERE

Mountain Valley MD to start husbandry animal trials to validate company’s...

Mountain Valley MD (CSE: MVMD- OTCQB: MVMDF) CEO Dennis Hancock and Director of Life Sciences Mike Farber joined Steve Darling from Proactive with news the company is planning to start husbandry animal trials with a third-party research organization to validate injectable solubilized Ivermectin...

2 days, 1 hour ago

2 min read